XTL Biopharmaceuticals Ltd (XTLB) stock
Close on Nov 11, 2026Market cap $15.71MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Dec 31, 2025
Valuation
- Market cap
- $15.71M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- EPS, diluted
- -$0.01
Trading
- Previous close
- $1.71
- Open
- $1.64
- Day's range
- $1.60 – $1.68
- Volume
- 5,807
- Average volume (20 days)
- 6,901
- Beta (5 years)
- 0.99
- 52-week range
- $1.52 – $5.64
- RSI (14 days)
- 41.3
- Volatility (1 year)
- 119.5%
- Relative volume
- 0.68×
- WACC
- 9.8%
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | XTLB | S&P 500 | Difference | XTLB per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -16.2% | -2.4% | −13.8 pts | ||
| 3 months | -37.4% | -1.2% | −36.2 pts | ||
| Year to date | -28.4% | +12.3% | −40.7 pts | ||
| 1 year | -58.1% | +12.4% | −70.5 pts | ||
| 3 years | -48.8% | +78.8% | −127.6 pts | -20.0% | +21.4% |
| 5 years | -88.4% | +75.2% | −163.6 pts | -35.0% | +11.9% |
| 10 years | -89.6% | +311.1% | −400.7 pts | -20.3% | +15.2% |
Twelve years at a glance
Fiscal years 2014 to 2025, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases XTL Biopharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About XTL Biopharmaceuticals
Pharmaceutical Preparations
XTL Biopharmaceuticals Ltd. is a biopharmaceutical company engaged in developing and commercializing therapeutic products. Through its operating entities, including its acquisitions of The Social Proxy and Psyga Bio Ltd., the company focuses on advancing drug development programs, such as early-stage psychedelic compounds and therapeutics. Its activities center on research and clinical development efforts, which rely on partnerships with contract research organizations and clinical trial sites. The company seeks to provide its pharmaceutical and healthcare solutions to patients and customers in target therapeutic markets.
Company profile, executives and historyXTL Biopharmaceuticals stock: common questions
What is XTL Biopharmaceuticals's stock price?
XTLB closed at $1.66 on Nov 11, 2026, down 2.64% on the day. Over the past 52 weeks it traded between $1.52 and $5.64.
What is XTL Biopharmaceuticals's market cap?
XTL Biopharmaceuticals was worth $15.71M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is XTLB's P/E ratio?
XTL Biopharmaceuticals lost money over fiscal 2025 (diluted EPS -$0.01), so it has no meaningful P/E ratio.
Does XTL Biopharmaceuticals pay a dividend?
No. XTL Biopharmaceuticals has not paid a cash dividend over the last twelve months.
How has XTLB stock performed over the past year?
Including dividends, XTLB returned -58.1% over the past year, against +12.4% for the S&P 500.
Who are XTL Biopharmaceuticals's competitors?
Companies most similar to XTL Biopharmaceuticals by business, industry and size include SCNX, MREO, CANF, SPRC, RDHL.
See a number that looks wrong?